CR20230192A - Formulación sólida - Google Patents

Formulación sólida

Info

Publication number
CR20230192A
CR20230192A CR20230192A CR20230192A CR20230192A CR 20230192 A CR20230192 A CR 20230192A CR 20230192 A CR20230192 A CR 20230192A CR 20230192 A CR20230192 A CR 20230192A CR 20230192 A CR20230192 A CR 20230192A
Authority
CR
Costa Rica
Prior art keywords
solid formulation
viral replication
pharmaceutical formulations
active pharmaceutical
pharmaceutical ingredient
Prior art date
Application number
CR20230192A
Other languages
English (en)
Inventor
Ivan Henri M Somers
Matthieu Jean M Ravelingien
Kristof Leonard Kimpe
Donghua Zhu
Sune Klint Andersen
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CR20230192A publication Critical patent/CR20230192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con formulaciones farmacéuticas que comprenden un ingrediente farmacéutico activo; y uno o una combinación de copolímero de ácido metacrílico, o un derivado de celulosa en donde el ingrediente farmacéutico activo es un inhibidor de la replicación viral del dengue. También se describen formas de dosificación sólidas que comprenden dichas formulaciones farmacéuticas, procesos para prepararlas y su uso en métodos de prevención y/o tratamiento y/o inhibición de la replicación viral.
CR20230192A 2020-11-04 2021-11-03 Formulación sólida CR20230192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/126596 WO2022094816A1 (en) 2020-11-04 2020-11-04 Solid formulation
PCT/CN2021/128521 WO2022095913A1 (en) 2020-11-04 2021-11-03 Solid formulation

Publications (1)

Publication Number Publication Date
CR20230192A true CR20230192A (es) 2023-10-26

Family

ID=78649077

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230192A CR20230192A (es) 2020-11-04 2021-11-03 Formulación sólida

Country Status (15)

Country Link
US (1) US20240000749A1 (es)
EP (1) EP4240331A1 (es)
JP (1) JP2023548348A (es)
KR (1) KR20230104226A (es)
CN (1) CN116685317A (es)
AU (1) AU2021376584A1 (es)
CA (1) CA3200538A1 (es)
CO (1) CO2023005726A2 (es)
CR (1) CR20230192A (es)
DO (1) DOP2023000084A (es)
MX (1) MX2023005219A (es)
PE (1) PE20231946A1 (es)
TW (1) TW202233178A (es)
UY (1) UY39503A (es)
WO (2) WO2022094816A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6933465B2 (ja) * 2013-12-31 2021-09-08 アセンディア ファーマシューティカルズ，エルエルシー 難水溶性化合物のための医薬組成物
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3305289A1 (en) * 2016-10-06 2018-04-11 Philipps-Universität Marburg Usage of silvestrol, episilvestrol and silvestrol analoga for the treatment of viral infections caused by viruses with cap-dependent translation
JP6820450B2 (ja) * 2017-09-14 2021-01-27 フェニックス・バイオテクノロジー・インコーポレイテッド ウイルス感染を治療するための方法および組成物
US20190365738A1 (en) * 2018-05-21 2019-12-05 Cadila Healthcare Limited Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof
CA3112485A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Crystalline forms of a farnesoid x receptor agonist
KR102173092B1 (ko) * 2018-11-20 2020-11-02 중앙대학교 산학협력단 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
CN111407728B (zh) * 2020-04-16 2022-02-22 重庆市畜牧科学院 一种替米考星肠溶性固体分散体及其制备方法和应用

Also Published As

Publication number Publication date
WO2022094816A1 (en) 2022-05-12
MX2023005219A (es) 2023-07-25
DOP2023000084A (es) 2023-11-15
CA3200538A1 (en) 2022-05-12
US20240000749A1 (en) 2024-01-04
AU2021376584A1 (en) 2023-06-29
PE20231946A1 (es) 2023-12-05
UY39503A (es) 2022-05-31
TW202233178A (zh) 2022-09-01
KR20230104226A (ko) 2023-07-07
CN116685317A (zh) 2023-09-01
CO2023005726A2 (es) 2023-05-29
WO2022095913A1 (en) 2022-05-12
EP4240331A1 (en) 2023-09-13
JP2023548348A (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2006044968A3 (en) Combination therapy for treating viral infections
CR20210480A (es) Formulaciones farmacéuticas
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
MX2023005219A (es) Formulacion solida.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
NZ751972A (en) Treatment of prurigo nodularis
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
HRP20201436T1 (hr) Makrogoli za davanje na sluznicu i njihove terapeutske primjene
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
EP3973976A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN EXTRACT OF CAMELLIA JAPONICA AS ACTIVE PRINCIPAL FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
FI3600276T3 (fi) Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
EP4230209A4 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION AND COMBINATION KIT FOR THE PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B
MX2022000663A (es) Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico.
WO2019035646A8 (ko) 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
JPWO2021060425A5 (es)
EA202191531A1 (ru) Терапевтически активные стероидные производные